Results 131 to 140 of about 19,507 (228)

Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring. [PDF]

JCEM Case Rep
Colorado M, Gomez Miranda J, Arias-Morales CE.   +2 more
europepmc   +1 more source

Postmarketing surveillance studies. [PDF]

BMJ, 1992
openaire   +1 more source

Postmarket Safety Actions for Novel Oncology Drugs Granted FDA's Accelerated Approval.

JAMA Netw Open
Mooghali M, Wallach JD, Mitchell AP, Ross JS, Ramachandran R.   +4 more
europepmc   +1 more source

Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis. [PDF]

Neurooncol Adv
Nishida Y, Kitajima A, Ishii T.
europepmc   +1 more source

Value of Clinical Evidence and Health Economics and Outcomes Research (HEOR) Studies. [PDF]

Muscle Nerve
Abrahao A, Ciepielewska M, Zinman L.
europepmc   +1 more source

Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Khan SM, Abboud I, Elhusseiny AM, Elhusseiny AM.   +3 more
europepmc   +1 more source

Effectiveness of Maternal Respiratory Syncytial Virus Vaccination in Conferring Infant Immunity: Review and Future Perspectives. [PDF]

Vaccines (Basel)
Kaneko M, Muraoka J.
europepmc   +1 more source

Beyond the label: ethical and clinical implications of off-label drug use in pediatric emergency care. [PDF]

Ital J Pediatr
Colombo M, Plebani A, Agosti M.
europepmc   +1 more source

A practical framework to approach the development and evaluation of patient registries for rare diseases. [PDF]

Orphanet J Rare Dis
Vaishnaw MS, Richesson R.
europepmc   +1 more source

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON [PDF]

, 2016

core   +1 more source